Orphazyme announces presentation of 2020 Annual Report

Orphazyme A/S
Investor news                                                                                                       
No. 03/2021                                                                                                           
Company Registration No. 32266355

 

Copenhagen, Denmark and Chicago, IL, USA, February 23, 2021 – Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative rare diseases, today announced that the Company will be hosting an investor call during which the Orphazyme management team will be presenting the Company’s 2020 Annual Report. The presentation will be followed by a Q&A session.

The call will be held on Tuesday, March 2, 2021 at 2.00 PM CET.

Dial-in details:

• Denmark: [phone]
• France: [phone]
• Netherlands: [phone]
• Standard International: [phone]
• Sweden: [phone]
• United Kingdom: [phone]
• United States: [phone]

Event Title: Orphazyme Annual Report 2020
Confirmation code: 8239516

The presentation will also be available via webcast: https://edge.media-server.com/mmc/p/kmp575pf   

After the call, the presentation will be available via the above link.

 

For additional information, please contact
Orphazyme A/S

Anders Vadsholt, CFO                                  [phone]